Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 1011-1020 of 9364

Page
per page
  1. NVP-AEW541
    A2278 NVP-AEW541
    Target: Insulin Receptor
    Summary: IGF-IR inhibitor, novel, potent and selective
      ≥22 mg/mL
  2. Brivanib Alaninate (BMS-582664)
    A2633 Brivanib Alaninate (BMS-582664)
    Summary: VEGFR2 inhibitor,ATP-competitive
      ≥22.05 mg/mL
  3. Epothilone A
    A1623 Epothilone A
    Summary: Microtubule stabilizing macrolide
      insoluble in H2O; ≥17.45 mg/mL
  4. PIK-90
    A2764 PIK-90
    Summary: PI3K inhibitor,potent selective
      insoluble in DMSO
  5. PIK-75 HCl
    A2080 PIK-75 HCl
    Summary: Inhibitor of PI3K isoform p110α
      insoluble in H2O; insoluble in EtOH; ≥8.15 mg/mL
  6. Canertinib (CI-1033)
    A1845 Canertinib (CI-1033)
    Summary: HER family tyrosine kinase inhibitor
  7. Zoledronic Acid
    A1352 Zoledronic Acid
    Target: Farnesyl Diphosphate Synthases
    Summary: Potent nitrogen-containing bisphosphonates
      insoluble in DMSO; insoluble in H2O; insoluble in EtOH
  8. IC-87114
    A2065 IC-87114
    Summary: PI3Kδ inhibitor
  9. Dimesna
    A1652 Dimesna
    Summary: Uroprotective agent
      insoluble in EtOH; ≥16.35 mg/mL
  10. Irinotecan
    A5133 Irinotecan
     1 Citation
    Summary: Topoisomerase I inhibitor
      insoluble in H2O; ≥11.4 mg/mL

Items 1011-1020 of 9364

Page
per page